Back to top
more

CONMED (CNMD)

(Delayed Data from NYSE)

$50.01 USD

50.01
563,299

-1.41 (-2.74%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $50.02 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Conmed (CNMD) Down 12.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Conmed (CNMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

New Strong Sell Stocks for February 19th

by Zacks Equity Research

ACDVF, BN and CNMD have been added to the Zacks Rank #5 (Strong Sell) List on February 19, 2024.

Zacks Equity Research

New Strong Sell Stocks for February 11th

by Zacks Equity Research

ATS, CNMD and CSX have been added to the Zacks Rank #5 (Strong Sell) List on February 11, 2025.

Zacks Equity Research

CNMD's Q4 Earnings & Sales Beat Estimates, Stock Down on Weak Outlook

by Zacks Equity Research

CONMED reports solid fourth-quarter results, fueled by strength in the General Surgery segment and continued demand for AirSeal product.

Zacks Equity Research

Here's What Key Metrics Tell Us About Conmed (CNMD) Q4 Earnings

by Zacks Equity Research

Although the revenue and EPS for Conmed (CNMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Conmed (CNMD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 11.67% and 1.36%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cardinal Health (CAH) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Cardinal (CAH) delivered earnings and revenue surprises of 10.29% and 0.69%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Conmed (CNMD) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Conmed (CNMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Should Value Investors Buy CONMED (CNMD) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Pro-Dex Stock Skyrockets Over the Past Year: A Must Buy?

by Zacks Equity Research

Investors can consider investing in PDEX right now as the stock has done extremely well through 2024 and its prospects continue to shine.

Zacks Equity Research

CNMD vs. ALGN: Which Stock Is the Better Value Option?

by Zacks Equity Research

CNMD vs. ALGN: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Cardinal Health (CAH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

Zacks Equity Research

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why Conmed (CNMD) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Here's Why You Should Retain CONMED Stock in Your Portfolio for Now

by Zacks Equity Research

CNMD is poised for growth on the back of strong product offerings and recurring revenues but faces headwinds from regulatory challenges, supply-chain constraints and cybersecurity risks.

Zacks Equity Research

Here's Why Conmed (CNMD) is a Strong Value Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Why Conmed (CNMD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Conmed (CNMD) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Why Conmed (CNMD) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why Conmed (CNMD) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View

by Zacks Equity Research

CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.

Zacks Equity Research

Conmed (CNMD) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Conmed (CNMD) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Conmed (CNMD) Surpasses Q3 Earnings Estimates

by Zacks Equity Research

Conmed (CNMD) delivered earnings and revenue surprises of 6.06% and 0.55%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?